(Gentamicin Sulfate with Betamethasone Valerate)
Keep out of reach of children and animals.
Store GenOne Spray bottle in an upright position
between 36 and 86 degrees F.
It is a violation of Federal
Law to use this product in a manner inconsistent with its labeling.
Gentamicin, one of the active ingredients in GenOne
Spray, is a broad-spectrum antibiotic. It is effective against a number
of gram-positive and gram-negative bacteria. Betamethasone, the product's
other active ingredient, is a synthetic corticosteroid that reduces
inflammation and itchiness associated with an infection when applied
For topical application in dogs only
GenOne is only for use on dogs. Do not use on cats
or other animals. Not for human use.
Read all package instructions and precautionary statements
Follow the instructions given in your veterinarian's
For the treatment of infected superficial lesions in dogs caused by bacteria sensitive to
If hypersensitivity to any of the components occurs, treatment with this product
should be discontinued and appropriate therapy instituted.
Dose and Administration
Prior to treatment, remove excessive hair and clean the lesion and
adjacent area. Hold bottle upright 3 to 6 inches from the lesion and depress the sprayer head twice. Administer 2
to 4 times daily for 7 days.
Each depression of the sprayer head delivers 0.7 mL of GenOne™ Spray.
GenOne™ Spray was well tolerated in an abraded skin study in dogs. No treatment-related
toxicological changes in the skin were observed.
Systemic effects directly related to treatment were confined to histological changes in the adrenals, liver, and
kidney and to organ-to-body weight ratios of adrenals. All were dose related, were typical for or not unexpected
with corticosteroid therapy, and were considered reversible with cessation of treatment.
Possible Side Effects
Side effects such as SAP and SGPT enzyme elevations, weight loss, anorexia, polydipsia,
and polyuria have occurred following parenteral or systemic use of synthetic corticosteroids in dogs. Vomiting
and diarrhea (occasionally bloody) have been observed in dogs.
Cushing’s syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.
Antibiotic susceptibility of the pathogenic organism(s) should be determined prior to the use
of this preparation. Use of topical antibiotics may permit overgrowth of non-susceptible bacteria, fungi, or
yeasts. If this occurs, treatment should be instituted with other appropriate agents as indicated.
Administration of recommended dose beyond 7 days may result in delayed wound healing. Animals treated
longer than 7 days should be monitored closely.
Avoid ingestion. Oral or parenteral use of corticosteroids, depending on dose, duration, and specific steroid may
result in inhibition of endogenous steroid production following drug withdrawal.
In patients presently receiving or recently withdrawn from systemic corticosteroid treatments, therapy with a
rapidly acting corticosteroid should be considered in especially stressful situations.
If ingestion should occur, patients should be closely observed for the usual signs of adrenocorticoid overdosage
which include sodium retention, potassium loss, fluid retention, weight gains, polydipsia, and/or polyuria.
Prolonged use or overdosage may produce adverse immunosuppressive effects.